metaPreg - Natalizumab during pregnancy

Natalizumab

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	5.51 [1.10, 27.66]	-	1 study	9	54	not evaluable	ROB	10.50 [1.43; .]
Major congenital malformations	2.88 [0.25, 32.65]	-	1 study	3	54	not evaluable	ROB	-
Minor congenital malformations	7.65 [0.87, 67.50]	-	1 study	6	54	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	0.84 [0.46, 1.52]	31%	2 studies	235	111	not evaluable	ROB	-
Low birth weight (< 2500g)	-	-	0 study					-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	-	-	0 study					-
Maternal consequences (as a whole)	3.50 [1.02, 12.05]	-	1 study	13	54	not evaluable	ROB	6.46 [1.15; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Elective/induced termination of pregnancy	2.26 [0.33, 15.52]	82%	2 studies	48	147	not evaluable	ROB	-
Intrauterine deaths (as a whole or unspecified)	1.63 [0.74, 3.58]	-	1 study	58	78	not evaluable	ROB	-
Early intrauterine death (< 22 weeks)	2.44 [0.90, 6.57]	-	1 study	19	69	not evaluable	ROB	-
Ectopic pregnancy	1.28 [0.03, 65.21]	-	1 study		69	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	0.42 [0.02, 10.50]	-	1 study	1	69	not evaluable	ROB	-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	6.37 [0.88, 46.18]	-	1 study	4	54	not evaluable	ROB	-
Hide endpoints reported in only one study ...